Bedfont Scientific Limited

Bedfont® now focuses on supporting clinical research, debuting at the 9th annual Outsourcing in Clinical Trials DACH in Basel.

Bedfont®, a world leader in breath analysis, announces its acquisition of coVita™, building on 16 years of partnership, market knowledge, and established infrastructure to support global expansion.

Demonstrating innovations in respiratory and allergy diagnostics with the NObreath® and Gastrolyzer® range.

Bedfont® celebrates global expansion by delivering UK healthcare solutions to a growing global audience.

Bedfont® Scientific Limited to showcase why the NObreath® is the FeNO device of choice at this year's global event.

Bedfont® appoints Michael Bencak to strengthen its position and accelerate growth

The NObreath® FeNO device offers a clear pathway to more effective asthma care, reducing over-reliance on blue inhalers.

Bedfont® Scientific Limited believes balanced teams drive better decision-making, stronger innovation, and long-term success.

Intermedical UK proudly delivers the 3,000th NObreath® FeNO device to the UK market.

coVita™ and Allergy Partners team up to improve asthma care in America